Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6278875 | 0.77 | SOAT1 (0.38) | MAPTNPC1L3MBTL1RAB9ACYP1A2 | |
| SCHEMBL4491895 | 0.71 | KMT2A (0.43) | LMNAL3MBTL1 | |
| SCHEMBL6282786 | 0.68 | — | — | |
| SCHEMBL29284013 | 0.68 | TDP1 (0.34) | — | |
| SCHEMBL30226488 | 0.68 | TDP1 (0.34) | — | |
| SCHEMBL3250049 | 0.67 | LMNA (0.34) | LMNATSHRMAPTNPC1L3MBTL1 | |
| SCHEMBL31219679 | 0.66 | MEN1 (0.36) | TSHRMAPTNPC1L3MBTL1RAB9A | |
| SCHEMBL1989695 | 0.65 | LMNA (0.34) | LMNATSHRMAPTNPC1L3MBTL1 | |
| SCHEMBL28999268 | 0.64 | RAB9A (0.36) | LMNATSHRMAPTNPC1L3MBTL1 | |
| SCHEMBL4983045 | 0.64 | NPSR1 (0.39) | LMNATSHRMAPTL3MBTL1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6969711-B2 | Cyclic diamine compounds and medicine containing the same | KOWA COMPANY, LTD. (JP) | 2005-11-29 | — | — | US | disclosed |
| US-20040038987-A1 | Novel cyclic diamine compounds and medicine containing the same | KOWA COMPANY, LTD. (JP) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038987-A1 | Novel cyclic diamine compounds and medicine containing the same | LCAT, ACAT2, ACAT1 | LMNA 4085/4885TSHR 3677/4885MAPT 1164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.